Since then, numerous clinical trials have evaluated the role of CD30-directed CAR-T, primarily for the treatment of classical Hodgkin lymphoma but also ALCL and other T-cell lymphomas in ongoing clinical trials. This evidence concerns the gene TNFRSF8 and anaplastic large cell lymphoma.